Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | MEN1 | O00255 | 8/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203358 | 0.95 | MEN1 (0.60) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL7035556 | 0.95 | MEN1 (0.60) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL7487588 | 0.92 | MEN1 (0.55) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL7035542 | 0.86 | MEN1 (0.52) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL10689705 | 0.86 | ALDH1A1 (0.66) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL29100113 | 0.83 | ALDH1A1 (0.62) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL19873004 | 0.83 | ALDH1A1 (0.62) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL12306020 | 0.83 | MEN1 (0.46) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL12428483 | 0.83 | MEN1 (0.46) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL12428487 | 0.83 | MEN1 (0.46) | MAPTALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | ELEX BIOTECH, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210139429-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | ELEX BIOTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210139429-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | ELEX BIOTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3774734-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | Elex Biotech, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111936466-A | Compounds for the treatment of cardiac arrhythmias and heart failure | 埃利克斯生物技术公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019191502-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | ELEX BIOTECH, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019191502-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | ELEX BIOTECH, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| EP-1192143-A1 | RHODANINE DERIVATIVES FOR USE IN A METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076987-A1 | RHODANINE DERIVATIVES FOR USE IN A METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139429-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | RYR2, RYR1, CACNA1F | MAPT 341/4885ALDH1A1 2527/4885MEN1 4315/4885 |
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | RYR2, RYR1, CACNA1F | MAPT 341/4885ALDH1A1 2527/4885MEN1 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.